Immunology/Inflammation

Immunology/Inflammation(免疫及炎症)

The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.

Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].

BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].

Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.

Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].

 

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.

[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.

[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.

[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.

[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.

[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.

[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.

[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.

研究方向

Immunology/Inflammation 相关产品(4245)

  • GC69316 structure
    GC69316JNJ-1013
    CAS: 2597343-08-1
    纯度: >99.00%

    JNJ-1013 是一种有效的选择性 IRAK1 降解剂,对 IRAK1、IRAK4、VHL FP 的 IC50 值分别为 72、443、1071 nM。JNJ-1013 诱导细胞凋亡 (Apoptosis) 并增加 cleavaged PARP 的表达。JNJ-1013 降低 IRAK1、p-IKBα、pSTAT3(Tyr705) 的表达。

  • GC69347 structure
    GC69347KYN-101
    CAS: 2247950-73-6
    纯度: >98.00%

    KYN-101 是一种有效的、选择性的和具有口服活性的 AHR 抑制剂。KYN-101 降低 CYP1A1 mRNA 表达。KYN-101 具有抗癌活性。

  • GC69364 structure
    GC69364LDCA
    CAS: 349106-80-5
    纯度: >99.00%

    LDCA 是一种双重打击代谢调节剂,可抑制 LDH-A 酶活性,刺激恶性群体的凋亡。LDCA 可用于致癌进展的研究。

  • GC69365 structure
    GC69365Lebrikizumab
    CAS: 953400-68-5
    纯度: >99.00%

    Lebrikizumab 是一种 IgG4 人源化单克隆抗体,可特异性结合白介素 13 (interleukin-13; IL-13) 并抑制其功能。Lebrikizumab 可用于哮喘的研究。

  • GC69379 structure
    GC69379Lipid 8
    CAS: 2226547-25-5
    纯度: >98.00%

    Lipid 8 是一种可电离的氨基脂质,可用于合成脂质纳米颗粒。

  • GC69380 structure
    GC69380Lirentelimab
    CAS: 2283348-97-8

    Lirentelimab (AK002) 是一种人源化 IgG1 单克隆抗体,靶向唾液酸结合的 Ig 样凝集素 8 (SIGLEC8)。Lirentelimab 诱导 IL-5 激活的嗜酸性粒细胞细胞凋亡并抑制 IL-5 介导的肥大细胞激活。Lirentelimab 可用于嗜酸性胃炎、十二指肠炎的研究。

  • GC69391 structure
    GC69391Lokivetmab
    CAS: 1533403-95-0

    Lokivetmab (Anti-Canine IL31 Recombinant Antibody) 是一种抗犬 IL-31 单克隆抗体,可用于犬的特应性皮炎 (AD) 研究。

  • GC69405 structure
    GC69405L-Theanine-d5
    CAS: 1217451-85-8
    纯度: >99.00%

    L-Theanine-d5 是 L-Theanine 的氘代物。L-Theanine (L-Glutamic Acid γ-ethyl amide)是一种存在绿茶叶片中的非蛋白氨基酸物质, 能阻断大脑中谷氨酸与谷氨酸受体结合,具有神经保护和抗氧化活性。 能通过口服 L-Theanine (L-Glutamic Acid γ-ethyl amide) 抑制皮层神经元兴奋从而产生抗应激作用 。

  • GC69413 structure
    GC69413Lusvertikimab
    CAS: 2375835-91-7
    纯度: >99.00%

    Lusvertikimab (OSE-127) 是一种人源化 IL7R 单克隆抗体。Lusvertikimab 不会被靶细胞内化并阻止 IL7R 异二聚化和随后的下游信号传导。Lusvertikimab 具有抗白血病功效,具有用于 B 细胞前体急性淋巴细胞白血病 (BCP-ALL) 研究的潜力。

  • GC69453 structure
    GC69453MethADP triammonium
    纯度: >99.00%

    MethADP (Adenosine 5'-(α,β-methylene)diphosphate) triammonium 是一种 CD73 抑制剂。MethADP 可用于 ATP-腺苷通路的研究。

  • GC69487 structure
    GC69487Moracin C
    CAS: 69120-06-5
    纯度: >99.00%

    Moracin C,一种天然产物,是一种抗炎剂。Moracin C 抑制 LPS 激活的活性氧 (ROS) 和一氧化氮 (NO) 从细胞中释放。

  • GC69530 structure
    GC69530N-Acetyldopamine dimer-2
    CAS: 916888-49-8

    N-Acetyldopamine dimer-2 (compound 2) 是具有抗氧化和抗炎活性的 N-acetyldopamine 二聚体可以从蝉皮的黄色粉末中分离出来。N-Acetyldopamine dimer-2 抑制氧化低密度脂蛋白 (LDL) 氧化、ROS 生成、NO 生成和 NF-κB 活性。

  • GC69534 structure
    GC69534Nadunolimab
    纯度: >98.00%

    Nadunolimab 是一种靶向 IL1RAP 的人 IgG1 单克隆抗体。Nadunolimab 阻断 IL-1α 和 IL-1β 信号并触发抗体依赖性细胞毒性。Nadunolimab 可用于癌症的研究。

  • GC69539 structure
    GC69539Nasunin
    CAS: 28463-30-1

    Nasunin 是一种抗氧化花青素、具有抗血管生成活性。

  • GC69555 structure
    GC69555NF-κB-IN-4

    NF-κB-IN-4 (化合物 17) 是一种有效的可透过血脑屏障的 NF-κB 通路抑制剂。NF-κB-IN-4 表现出潜在的低毒性抗神经炎症活性。NF-κB-IN-4 可阻断 IκBα 的激活和磷酸化,降低 NLRP3 的表达,从而抑制 NF-κB 的激活。NF-κB-IN-4 可用于神经炎症相关疾病的研究。

  • GC69556 structure
    GC69556NF-κB/MAPK-IN-1
    CAS: 2413940-56-2
    纯度: >98.00%

    NF-κB/MAPK-IN-1 (compound 11a) 是一种有效的 NF-κB 和 MAPK 通路抑制剂。NF-κB/MAPK-IN-1 对 NO 生成具有抑制作用,其 IC50 为6.96 μM。NF-κB/MAPK-IN-抑制 LPS 诱导的 iNOS,COX-2,ERκ 和 P38 激活。 NF-κB/MAPK-IN-1 可抑制 LPS 诱导的巨噬细胞炎症反应。 NF-κB/MAPK-IN-1 可用于类风湿关节炎 (RA) 的研究。

  • GC69561 structure
    GC69561Nidanilimab
    CAS: 2171061-85-9
    纯度: >99.00%

    Nidanilimab (CAN04) 是一种完全人源化的单克隆抗 IL1RAP 抗体,其 Kd 值为 1.10 pM。Nidanilimab 阻断 IL1α 和 IL1β 信号通路,并刺激免疫系统破坏肿瘤细胞。Nidanilimab 可用于非小细胞肺癌 (NSCLC) 和胰腺导管腺癌 (PDAC) 的研究。

  • GC69569 structure
    GC69569NLRP3/AIM2-IN-2
    CAS: 791840-86-3
    纯度: >99.00%

    NLRP3/AIM2-IN-2是一种对 NLRP3 和 AIM2 炎症小体依赖性细胞焦亡具有不同物种特异性作用的新型强效抑制剂,其IC50值为 0.2392 ±0.0233μM。

  • GC69570 structure
    GC69570NLRP3-IN-10
    CAS: 2641826-39-1

    NLRP3-IN-10 是一种强效的 NLRP3 抑制剂,抑制 IL-1β 的 IC50 为 251.1 nM。NLRP3-IN-10 能够减弱ASC斑点形成抑制NLRP3炎症小体激活。

  • GC69571 structure
    GC69571NLRP3-IN-11
    CAS: 2769040-91-5
    纯度: >98.00%

    NLRP3-IN-11 是一种 NLRP3 蛋白抑制剂。NLRP3-IN-11 具有生物活性,IC50 值 <0.3 μM。NLRP3-IN-11 可用于炎症和退行性疾病的研究,包括 NASH、动脉粥样硬化和其他心血管疾病、阿尔茨海默病、帕金森病、糖尿病、痛风和许多其他自身炎症性疾病。

  • GC69572 structure
    GC69572NLRP3-IN-13
    CAS: 1704638-35-6
    纯度: >99.50%

    NLRP3-IN-13 (参考专利中的化合物 C77) 是一种有效的选择性 NLRP3 抑制剂 (IC50: 2.1 μM)。NLRP3-IN-13 抑制 NLRP3 和 NLRC4 炎性体,并抑制 NLRP3 介导的 IL-1β 产生。NLRP3-IN-13 还抑制 NLRP3 ATPase 活性。NLRP3-IN-13可用于神经炎症疾病的研究。

  • GC69573 structure
    GC69573NLRP3-IN-18
    CAS: 2769040-06-2

    NLRP3-IN-18 (compound 13) 是一种有效的 NLRP3 抑制剂,IC50 值为 ≤ 1.0 µM[1] 。

  • GC69582 structure
    GC69582ARC186
    纯度: >94.00%

    ARC 186 是一种核酸适配体,是高效的补体抑制剂,通过阻断转化酶催化的C5 激活发挥作用。

  • GC69590 structure
    GC69590Nrf2 activator-2
    CAS: 2770448-53-6
    纯度: >98.00%

    Nrf2 activator-2 (compound O15) 是一种蛇床子素衍生物,一种有效的 Nrf2 激动剂,在 293 T 细胞中的 EC50 为 2.9 μM。Nrf2 activator-2有效抑制 Keap1 和 Nrf2 的相互作用,从而显示出对 Nrf2 的激活作用。Nrf2 activator-2 显示细胞中泛素化 Nrf2 水平显着降低。